SYSTEM AND METHOD FOR MONITORING GLUCOSE OR OTHER COMPOSITIONS IN AN INDIVIDUAL

• US 20140031658A1
• Filed: 04/11/2012
• Published: 01/30/2014
• Est. Priority Date: 04/12/2011
• Status: Abandoned Application

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Zheng, Hui, Schoenfeld, David A., Nathan, David M.
• Application Number:
  US14/110,801
• Publication Number:
  US 20140031658A1
• Time in Patent Office: Days
• US Class Current: 600/365
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: G16H 15/00 ICT specially adapted for medical reports, e.g. generation or transmission thereof
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

A system and method for modeling a blood glucose (BG) level of an individual is presented. A continuous glucose monitor (CGM) device is configured to monitor a blood glucose level of the individual. A processor is configured to receive CGM data of the individual from the CGM device, smooth the CGM data into a plurality of continuous curves, and generate an individual-level model of a BG profile of the individual using the plurality of continuous curves. The processor is configured to estimate the average blood glucose curve and inter-day variance-covariance of BG within the individual using the individual-level model, and generate a report based on the average blood glucose curve and inter-day variance-covariance of BG within the individual.

Claims

1. A system for modeling a blood glucose (BG) level of an individual, comprising:

a continuous glucose monitor (CGM) device configured to monitor a blood glucose level of the individual;

a processor, the processor being configured to;

receive CGM data of the individual from the CGM device,

smooth the CGM data into a plurality of continuous curves,

generate an individual-level model of a BG profile of the individual using the plurality of continuous curves,

estimate inter-day variance-covariance of BG within the individual using the individual-level model, and

generate a report based on the inter-day variance-covariance of BG within the individual.

2. The system of claim 1, wherein the processor is configured to:

generate a group-level model using the plurality of continuous curves; and

estimate a group-wide glucose profile using the group-level model.

3. The system of claim 1, wherein the CGM data of the individual includes data collected over a period of time exceeding three days.

4. The system of claim 1, wherein the continuous curves include B-spline curves.

5. The system of claim 4, wherein the B-spline curves are derived recursively using a De Boor algorithm.

6. The system of claim 1, wherein the processor is configured to use the estimation of inter-day variance-covariance of BG to identify a time to administer a treatment to the individual.

7. The system of claim 6, including an injection apparatus configured to receive an instruction from the processor to administer a treatment.

8. A method for modeling a blood glucose (BG) level of an individual, comprising the steps of:

capturing continuous glucose monitoring (CGM) data of the individual;

smoothing the CGM data into a plurality of spline curves;

generating an individual-level model of a BG profile of the individual using the plurality of spline curves;

estimating inter-day variance-covariance of BG within the individual using the individual-level model; and

generating a report based on the step of estimating.

9. The method of claim 8, including:

generating a group-level model using the plurality of spline curves; and

estimating a group-wide glucose profile using the group-level model.

10. The method of claim 8, including analyzing inter-day variance-covariance of BG within the individual to determine a probability of the BG of the individual exceeding a predetermined maximum or minimum value.

11. The method of claim 10, wherein the maximum value is 110-160 mg/dL.

12. The method of claim 10, wherein the minimum value is 40-70 mg/dL.

13. The method of claim 8, wherein the spline curves include B-spline curves.

14. The method of claim 13, wherein the B-spline curves are derived recursively using a De Boor algorithm.

15. The method of claim 8, including using the estimation of inter-day variance-covariance of BG within the individual to identify a time to administer a treatment to the individual.